Effects of end stage renal disease and aluminium hydroxide on triazolam pharmacokinetics.
Open Access
- 1 June 1985
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 19 (6) , 839-842
- https://doi.org/10.1111/j.1365-2125.1985.tb02725.x
Abstract
Triazolam 0.5 mg was administered to 11 dialysis patients and 11 age, weight and sex matched controls. Peak plasma concentrations (Cmax) were higher in control subjects, but there were no other differences between the groups. When dialysis patients took triazolam with 3600 mg aluminum hydroxide suspension, Cmax and AUC were increased into the range observed in control subjects. It appears that triazolam can be used at normal doses in patients with renal dysfunction, without regard to interaction with aluminum hydroxide gel, or to alterations in elimination.Keywords
This publication has 10 references indexed in Scilit:
- Triazolam protein binding and correlation with alpha-1 acid glycoprotein concentrationClinical Pharmacology & Therapeutics, 1984
- Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolamPsychopharmacology, 1983
- Ranitidine influences the uptake of oral midazolam.British Journal of Clinical Pharmacology, 1983
- Kinetics and Mechanism of the Equilibrium Reaction of Triazolam in Aqueous SolutionJournal of Pharmaceutical Sciences, 1982
- PharmacokineticsPublished by Taylor & Francis ,1982
- Electron-capture gas chromatographic analysis of the triazolobenzodiazepines alprazolam and triazolamJournal of Chromatography B: Biomedical Sciences and Applications, 1981
- Triazolam dispositionClinical Pharmacology & Therapeutics, 1981
- Diazepam absorption: Effect of antacids and foodClinical Pharmacology & Therapeutics, 1978
- Influence of magnesium and aluminum hydroxide mixture on chlordiazepoxide absorptionClinical Pharmacology & Therapeutics, 1976